<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2501221641
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPEX 10 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        222.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAMMAM PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1898]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>ARIPEX is one of a group of medicines called antipsychotics. </strong>It is used to treat adults and adolescents 15 years and older who suffer from a disease characterized by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behavior and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense.</p><p>&nbsp;</p><p>ARIPEX is used to treat adults who suffer from a condition with symptoms such as feeling &quot;high&quot;, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. It also prevents this condition from returning in patients who have responded to the treatment with ARIPEX.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Do not take ARIPEX </strong></p><p>▪ If you are allergic (hypersensitive) to aripiprazole or any of the other ingredients of ARIPEX (listed in section 6).</p><p>&nbsp;</p><p><strong>Take special care with ARIPEX </strong></p><p>Before treatment with ARIPEX, tell your doctor if you suffer from</p><p>▪ High blood sugar (characterized by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite, and feeling weak) or family history of diabetes</p><p>▪ Seizure</p><p>▪ Involuntary, irregular muscle movements, especially in the face</p><p>▪ Cardiovascular diseases, family history of cardiovascular disease, stroke or &quot;mini&quot; stroke, abnormal blood pressure</p><p>▪ Blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots</p><p>▪ Past experience of excessive gambling</p><p>&nbsp;</p><p>If you notice you are gaining weight, experience any difficulty in swallowing or allergic symptoms, please tell your doctor.</p><p>&nbsp;</p><p>If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you or your carer/relative should tell your doctor if you have ever had a stroke or &quot;mini&quot; stroke.</p><p>&nbsp;</p><p>Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself. Suicidal thoughts and behaviors have been reported during aripiprazole treatment.</p><p>&nbsp;</p><p>Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever, sweating, altered mental status, or very rapid or irregular heart beat.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>ARIPEX is not for use in children and adolescents under 13 years. Ask your doctor or pharmacist for advice before taking ARIPEX.</p><p><strong>&nbsp;</strong></p><p><strong>Taking other medicines </strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Blood pressure-lowering medicines: ARIPEX may increase the effect of medicines used to lower the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure under control.</p><p>&nbsp;</p><p>Taking ARIPEX with some medicines may need to change your dose of ARIPEX. It is especially important to mention the following to your doctor:</p><p>&nbsp;</p><p>▪ Medicines to correct heart rhythm</p><p>▪ Antidepressants or herbal remedy used to treat depression and anxiety</p><p>▪ Antifungal agents</p><p>▪ Certain medicines to treat HIV infection</p><p>▪ Anticonvulsants used to treat epilepsy</p><p>&nbsp;</p><p>Medicines that increase the level of serotonin: triptans, tramadol, tryptophan, SSRIs (such as paroxetine and fluoxetine), tricyclics (such as clomipramine, amitriptyline), pethidine, St John&rsquo;s Wort and venlafaxine. These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with ARIPEX tablets, you should see your doctor.</p><p>&nbsp;</p><p><strong>Taking ARIPEX with food and drink </strong></p><p>ARIPEX can be taken regardless of meals.</p><p>Alcohol should be avoided when taking ARIPEX.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding </strong></p><p><strong>You should not take ARIPEX if you are pregnant </strong>unless you have discussed this with your doctor. Be sure to tell your doctor immediately if you are pregnant, think you may be pregnant, or if you are planning to become pregnant.</p><p>The following symptoms may occur in newborn babies, of mothers that have used ARIPEX in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Be sure to tell your doctor immediately if you are breast-feeding. </strong></p><p>&nbsp;</p><p>If you are taking ARIPEX, you should not breast-feed.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines </strong></p><p>Do not drive or use any tools or machines, until you know how ARIPEX affects you.</p><p><strong>&nbsp;</strong></p><p><strong>Important information about some of the ingredients of ARIPEX</strong></p><p>If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take ARIPEX exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Adults</strong>:</p><p><strong>The usual dose is 15 mg once a day. </strong>However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p>&nbsp;</p><p><strong>Children and adolescents: </strong></p><p>ARIPEX may be started at a low dose. The dose may be gradually increased to the usual dose for adolescents of 10 mg once a day. However, your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p>&nbsp;</p><p>If you have the impression that the effect of ARIPEX is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Try to take the ARIPEX tablet at the same time each day. </strong>It does not matter whether you take it with or without food. Always take the tablet with water and swallow it whole.</p><p>&nbsp;</p><p><strong>Even if you feel better, </strong>do not alter or discontinue the daily dose of ARIPEX without first consulting your doctor.</p><p>&nbsp;</p><p><strong>If you take more ARIPEX than you should </strong></p><p>If you realize you have taken more ARIPEX tablets than your doctor has recommended (or if someone else has taken some of your ARIPEX tablets), contact your doctor right away. If you cannot reach your doctor, go to the nearest hospital and take the pack with you.</p><p>&nbsp;</p><p><strong>If you forget to take ARIPEX </strong></p><p>If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>ARIPEX tablets</strong></p><p>Do not stop your treatment just because you feel better. It is important that you carry on taking your ARIPEX tablets for as long as your doctor has told you to.</p><p>&nbsp;</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist. </strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ARIPEX can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><p>&bull; diabetes mellitus,</p><p>&bull; difficulty sleeping,</p><p>&bull; feeling anxious,</p><p>&bull; feeling restless and unable to keep still, difficulty sitting still,</p><p>&bull; uncontrollable twitching, jerking or writhing movements, restless legs,</p><p>&bull; trembling,</p><p>&bull; headache,</p><p>&bull; tiredness,</p><p>&bull; sleepiness,</p><p>&bull; light-headedness,</p><p>&bull; shaking and blurred vision,</p><p>&bull; decreased number of or difficulty making bowel movements,</p><p>&bull; indigestion,</p><p>&bull; feeling sick,</p><p>&bull; more saliva in mouth than normal,</p><p>&bull; vomiting,</p><p>&bull; feeling tired.</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><p>&bull; increased blood levels of the hormone prolactin,</p><p>&bull; too much sugar in the blood,</p><p>&bull; depression,</p><p>&bull; altered or increased sexual interest,</p><p>&bull; uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia),</p><p>&bull; muscle disorder causing twisting movements (dystonia),</p><p>&bull; double vision,</p><p>&bull; fast heart beat,</p><p>&bull; a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting,</p><p>&bull; hiccups.</p><p>&nbsp;</p><p>The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known:</p><p>&nbsp;</p><p>&bull; low levels of white blood cells,</p><p>&bull; low levels of blood platelets,</p><p>&bull; allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),</p><p>&bull; onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,</p><p>&bull; high blood sugar,</p><p>&bull; not enough sodium in the blood,</p><p>&bull; loss of appetite (anorexia),</p><p>&bull; weight loss,</p><p>&bull; weight gain,</p><p>&bull; thoughts of suicide, suicide attempt and suicide,</p><p>&bull; excessive gambling,</p><p>&bull; feeling aggressive,</p><p>&bull; agitation,</p><p>&bull; nervousness,</p><p>&bull; combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome),</p><p>&bull; seizure,</p><p>&bull; serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),</p><p>&bull; speech disorder,</p><p>&bull; sudden unexplained death,</p><p>&bull; life-threatening irregular heart beat,</p><p>&bull; heart attack,</p><p>&bull; slower heart beat,</p><p>&bull; blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately),</p><p>&bull; high blood pressure,</p><p>&bull; fainting,</p><p>&bull; accidental inhalation of food with risk of pneumonia (lung infection),</p><p>&bull; spasm of the muscles around the voice box,</p><p>&bull; inflammation of the pancreas,</p><p>&bull; difficulty swallowing,</p><p>&bull; diarrhoea,</p><p>&bull; abdominal discomfort,</p><p>&bull; stomach discomfort,</p><p>&bull; liver failure,</p><p>&bull; inflammation of the liver,</p><p>&bull; yellowing of the skin and white part of eyes,</p><p>&bull; reports of abnormal liver tests values,</p><p>&bull; skin rash,</p><p>&bull; sensitivity to light,</p><p>&bull; baldness,</p><p>&bull; excessive sweating,</p><p>&bull; abnormal muscle breakdown which can lead to kidney problems,</p><p>&bull; muscle pain,</p><p>&bull; stiffness,</p><p>&bull; involuntary loss of urine (incontinence),</p><p>&bull; difficulty in passing urine,</p><p>&bull; withdrawal symptoms in newborn babies in case of exposure during pregnancy,</p><p>&bull; prolonged and/or painful erection,</p><p>&bull; difficulty controlling core body temperature or overheating,</p><p>&bull; chest pain,</p><p>&bull; swelling of hands, ankles or feet,</p><p>&bull; in blood tests: fluctuating blood sugar, increased glycosylated haemoglobin.</p><p>In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In addition, cases of stroke or &quot;mini&quot; stroke have been reported.</p><p>&nbsp;</p><p><strong>Additional side effects in children and adolescents </strong></p><p>Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (greater than 1 in 100 patients).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C</p><p>Keep out of the reach and sight of children.</p><p>Do not use ARIPEX after the expiry date which is stated on the blister and on the carton.</p><p>Store in the original package in order to protect from moisture.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>▪ The active substance is aripiprazole.</p><p>ARIPEX 5 mg tablets: each tablet contains 5 mg of aripiprazole.</p><p>ARIPEX 10 mg tablets: each tablet contains 10 mg of aripiprazole.</p><p>ARIPEX 15 mg tablets: each tablet contains 15 mg of aripiprazole.</p><p>▪ The other ingredients are Magnesium Stearate, Avicel PH 102, Croscarmellose Sodium Type A, Red Iron Oxide, Yellow Iron Oxide, Lactose Fast Flow, and Spectracol Brilliant Blue LK815030.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ARIPEX 5 mg tablets are light blue, round, biconvex uncoated tablets engraved with "T32"on one side and plain on the other side.
ARIPEX 10 mg tablets are a light pink, round, biconvex uncoated tablets engraved with "T33"on one side and plain on the other side.
ARIPEX 15 mg tablets are a light yellow, round, biconvex uncoated tablets engraved with "T34"on one side and plain on the other side.


Each pack contains 30 tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p><strong>DAMMAM Pharma </strong></p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2017.                 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>أريبيكس هو دواء ينتمي إلى مجموعة من الأدوية تسمى </strong><strong>مضادات الذهان. </strong>يستخدم هذا الدواء لعلاج البالغين والمراهقين من سن 15 سنة فما فوق الذين يعانون من مرض تتميز أعراضه على سبيل المثال بسماع أو رؤية أو الإحساس بأشياء ليس لها وجود، الارتياب أو المعتقدات الخاطئة، عدم ترابط الكلام والسلوك ورتابة العاطفة.</p><p dir="RTL">الناس المصابون بتلك الحالة قد يعانون أيضا من الشعور بالاكتئاب أو الشعور بالذنب أو بالقلق أو التوتر.</p><p dir="RTL"><strong>أريبيكس</strong> يستخدم لعلاج البالغين الذين يعانون من حالة تتميز بأعراض معينة مثل: الشعور بالاستعلاء أو وجود كميات مفرطة من الطاقة أو الحاجة إلى النوم بشكل أقل بكثير من المعتاد أو التحدث بشكل شديد السرعة مع تسابق فى الأفكار المقترن أحيانا بسرعة انفعال حادة. يستخدم أيضا ليمنع هذه الحالة من العودة مرة أخرى إلى المرضى الذين استجابوا للعلاج بأريبيكس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم بتناول أقراص أريبيكس فى الحالات الآتية:</strong></p><ul><li dir="RTL">إذا كنت تعانى من فرط التحسس تجاه أريبيبرازول<strong> </strong>أو أي من المكونات الأخرى لأريبيكس (المدرجة في الفقرة 6).</li></ul><p dir="RTL"><strong>ينبغى توخى الحذر عند تناول أقراص أريبيكس</strong></p><p dir="RTL">قبل العلاج بأقراص أريبيكس أخبر طبيبك المعالج إذا كنت تعاني من أى من الحالات الآتية:</p><ul><li dir="RTL">ارتفاع ضغط الدم (وتتميز أعراضه على سبيل المثال بالعطش الشديد وإفراز كميات كبيرة من البول وزيادة الشهية والإحساس بالضعف) أو يكون لديك تاريخ عائلى للإصابة بمرض السكرى.</li><li dir="RTL">نوبات صرع.</li><li dir="RTL">حركة فى العضلات بشكل غير منتظم ولا إرادى، خصوصا بالوجه.</li><li dir="RTL">&nbsp;أمراض القلب والأوعية الدموية أو تاريخ عائلى للإصابة بأمراض القلب والأوعية الدموية أو السكتة الدماغية أو السكتة الدماغية البسيطة أو خلل فى ضغط الدم.</li><li dir="RTL">تجلط الدم أو تاريخ عائلى للإصابة بجلطات الدم حيث ترتبط مضادات الذهان بتكوين جلطات الدم.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجربة سابقة للقمار المفرط</p><p dir="RTL">إذا لاحظت أنك تزداد فى الوزن أو تعاني من صعوبة فى البلع أو لديك أعراض حساسية فضلا أخبر طبيبك المعالج.</p><p dir="RTL">إذا كنت من كبار السن المصابين بالخرف (وهو فقدان الذاكرة والقدرات العقلية الأخرى) فإنه يجب عليك أنت أو أى من أقربائك ممن يقومون برعايتك إخبار الطبيب المعالج فى حالة إصابتك فى أى وقت من الأوقات بالسكتة الدماغية سواء كانت بسيطة أو غير ذلك.</p><p dir="RTL">أخبر طبيبك المعالج فورا إذا راودتك أفكار أو أحاسيس تتجه نحو إلحاق الضرر بنفسك. حيث أنه تم رصد تقارير عن أفكار الانتحار أثناء العلاج بأريبيبرازول.</p><p dir="RTL">أخبر طبيبك المعالج فورا إذا كنت تعاني من تيبس بالعضلات المقترن بارتفاع درجة الحرارة والتعرق، وتغيير الحالة النفسية، أو السرعة الشديدة فى ضربات القلب أوعدم انتظام ضربات القلب.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا يستخدم أريبيكس فى حالة الأطفال والمراهقين تحت سن 13 سنة. اسأل الطبيب أو الصيدلى للنصيحة قبل تناول أقراص أريبيكس.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">فضلا أخبر طبيبك المعالج أو الصيدلى فى حالة تناولك مسبقا أو حاليا أى أدوية أخرى. بما فى ذلك الأدوية التى حصلت عليها بدون وصفة طبية.</p><p dir="RTL">الأدوية المستخدمة لتقليل ضغط الدم: أريبيكس قد يتسبب فى زيادة تأثير الأدوية التى تعمل على تقليل ضغط الدم. تأكد من إخبار طبيبك المعالج إذا كنت تتناول دواء للسيطرة على ضغط الدم.</p><p dir="RTL">تناول أقراص أريبيكس مع بعض الأدوية قد يحتاج إلى تغيير الجرعة الموصوفة لك من أقراص أريبيكس. من المهم بصفة خاصة إخبار الطبيب المعالج فى حالة تناول أي من الأدوية التالية:</p><ul><li dir="RTL">الأدوية التى تعمل على تصحيح ضربات القلب.</li><li dir="RTL">مضادات الاكتئاب أو الأدوية العشبية التى تستخدم لعلاج الاكتئاب والقلق.</li><li dir="RTL">مضادات الفطريات.</li><li dir="RTL">بعض الأدوية المستخدمة فى علاج الإصابة بفيروس نقص المناعة.</li><li dir="RTL">مضادات التشنجات والتى تستخدم لعلاج الصرع.</li></ul><p dir="RTL">الأدوية التي تزيد من مستوى السيروتونين: أدوية تريبتان، ترامادول، تريبتوفان، إس إس آرآي (مثل باروكستين وفلوكستين)، الأدوية ثلاثية الحلقات (مثل كلوميبرامين، أميتريبتيلين)، بيثيدين، نبتة القديس جون وفينلافاكسين. هذه الأدوية تزيد من خطر الأعراض الجانبية. إذا كان لديك أي أعراض غير عادية من تناول أي من هذه الأدوية مع أقراص زولندا، يجب عليك مراجعة الطبيب.</p><p dir="RTL"><strong>تناول أقراص أريبيكس مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول أقراص أريبيكس بصرف النظر عن وجبات الطعام.</p><p dir="RTL">يجب تجنب تناول الكحول أثناء العلاج بأريبيكس.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يجب عدم تناول أقراص أريبيكس فى حالة الحمل إلا فى حالة مناقشة هذا الأمر مع الطبيب المعالج. صعوبة في التغذية ما إذا كنت حامل أو تعتقدين أنك حامل أو تخططين إلى أن تصبحى حامل.</p><p dir="RTL">الأعراض الآتية قد تحدث للأطفال حديثى الولادة الذين خضعت أمهاتهم للعلاج بأقراص أريبيكس فى المرحلة الأخيرة من الحمل (وهي الثلاثة أشهر الأخيرة من الحمل): ارتعاش، تيبس العضلات و/أو ضعف ونعاس وتهيج ومشاكل فى التنفس وصعوبة في التغذية. عند ظهور أى من هذه الأعراض لطفلك فقد تحتاجين إلى التواصل مع الطبيب.</p><p dir="RTL"><strong>تأكدى من إخبار طبيبك المعالج على الفور فى حالة إرضاعك لطفلك طبيعيا</strong></p><p dir="RTL">يجب الامتناع عن الرضاعة الطبيعية فى حالة العلاج بأريبيكس.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong>لا تقم بقيادة السيارة أو استخدام أى أدوات أو آلات لحين معرفة مدى تأثير أقراص أريبيكس عليك.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات اقراص أريبيكس</strong></p><p dir="RTL">فى حالة إخبارك من قبل طبيبك المعالج بعدم تحملك لبعض أنواع السكر، تواصل مع طبيبك المعالج قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائما بتناول أقراص أريبيكس تماما كما أخبرك طبيبك المعالج. إذا كنت غير واثق يجب عليك التحقق من خلال الطبيب أو الصيدلى.</p><p dir="RTL"><strong>فى حالة البالغين:</strong></p><p dir="RTL"><strong>الجرعة المعتادة هى 15 ملجم مرة واحدة يوميا.</strong> رغم ذلك قد يلجأ طبيبك المعالج إلى وصف جرعة أكبر أو أقل على ألا تزيد الجرعة اليومية عن 30 ملجم مرة واحدة يوميا.</p><p dir="RTL"><strong>في</strong><strong> حالة</strong> <strong>الأطفال</strong><strong> </strong><strong>والمراهقين</strong><strong>:</strong></p><p dir="RTL">قد تكون جرعة البداية من أقراص أريبيكس قليلة. والتى قد تزداد تدريجيا إلى أن تصل إلى الجرعة المعتادة للمراهقين وهي 10 ملجم مرة واحدة يوميا. رغم ذلك قد يلجأ طبيبك المعالج إلى وصف جرعة أكبر أو أقل على ألا تزيد الجرعة اليومية عن 30 ملجم مرة واحدة يوميا.</p><p dir="RTL">فى حالة اعتقادك بشدة قوة أو شدة ضعف تأثير أقراص أريبيكس عليك، تواصل مع طبيبك المعالج أو الصيدلى.</p><p dir="RTL"><strong>حاول أن تتناول قرص أريبيكس فى نفس الوقت كل يوم.</strong> حيث أنه لا يهم ما إذا كنت تتناولها مع أو بدون الطعام. قم دائما بتناول القرص مع الماء وابتلعه كاملا.</p><p dir="RTL"><strong>حتى فى حالة شعورك بتحسن،</strong> لا تقم بتغيير الجرعة اليومية أو التوقف عن تناولها بدون استشارة طبيبك المعالج أولا.</p><p dir="RTL"><strong>فى حالة تناولك لأقراص أريبيكس أكثر مما ينبغى</strong></p><p dir="RTL">إذا أدركت أنك قد تناولت أقراص أريبيكس بشكل أكثر مما أوصى به طبيبك المعالج (أو إذا قام شخص آخر بتناول بعض من أقراص أريبيكس)، تواصل مع الطبيب فى الحال. وإذا لم تستطع الوصول إلى الطبيب توجه إلى أقرب مستشفى وبحوذتك علبة الدواء.</p><p dir="RTL"><strong>فى حالة نسيانك تناول أقراص أريبيكس</strong></p><p dir="RTL">فى حالة تفويت جرعة، قم بتناول الجرعة الفائتة حالما تتذكر ولكن لا تتناول جرعتين فى يوم واحد.</p><p dir="RTL"><strong>إذا توقفت عن تناول أقراص أريبيكس</strong></p><p dir="RTL">لا تتوقف عن العلاج الخاص بك فقط لأنك تشعر بأنك أفضل. من المهم أن تداوم على تناول أقراص زولندا الخاصة بك طالما قال لك طبيبك ذلك.</p><p dir="RTL"><strong>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء اسأل الطبيب أو الصيدلى بشأنها.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، أريبيكس قد يسبب آثار جانبية، وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</strong></p><p dir="RTL">&bull; السكرى،</p><p dir="RTL">&bull; صعوبة النوم،</p><p dir="RTL">&bull; الشعور بالقلق،</p><p dir="RTL">&bull; الشعور بعدم الراحة وعدم القدرة على الحفاظ على الهدوء، وصعوبة الجلوس هادئا،</p><p dir="RTL">&bull; رعشة لا يمكن السيطرة عليها، التشنج أو الرجيج أو التواء الحركات، توتر الساقين،</p><p dir="RTL">&bull; الارتجاف،</p><p dir="RTL">&bull; صداع الرأس،</p><p dir="RTL">&bull; التعب،</p><p dir="RTL">&bull; النعاس،</p><p dir="RTL">&bull; الدوار،</p><p dir="RTL">&bull; الاهتزاز وعدم وضوح الرؤية،</p><p dir="RTL">&bull; انخفاض عدد أو صعوبة حركات الأمعاء،</p><p dir="RTL">&bull; عسر الهضم،</p><p dir="RTL">&bull; الشعور بالمرض،</p><p dir="RTL">&bull; زيادة اللعاب في الفم عن المعتاد،</p><p dir="RTL">&bull; القيء،</p><p dir="RTL">&bull; الشعور بالتعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة (قد تؤثر على ما يصل إلى 1 من 100 شخص):</strong></p><p dir="RTL">&bull; زيادة مستويات هرمون البرولاكتين في الدم،</p><p dir="RTL">&bull; ارتفاع السكر في الدم،</p><p dir="RTL">&bull; الإكتئاب،</p><p dir="RTL">&bull; تغير أو زيادة الاهتمام الجنسي،</p><p dir="RTL">&bull; حركات لا يمكن السيطرة عليها من الفم واللسان والأطراف (خلل الحركة المتأخر)،</p><p dir="RTL">&bull; اضطراب العضلات مما يتسبب في حركات التواء (خلل التوتر)،</p><p dir="RTL">&bull; رؤية مزدوجة،</p><p dir="RTL">&bull; سرعة دقات القلب،</p><p dir="RTL">&bull; انخفاض في ضغط الدم عند الوقوف مما يسبب الدوخة، والدوار أو الإغماء،</p><p dir="RTL">&bull; الفواق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تم الإبلاغ عن الأعراض الجانبية التالية منذ تسويق أريبيبرازول عن طريق الفم ولكن معدل حدوثهم غير معروف:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; انخفاض مستويات خلايا الدم البيضاء،</p><p dir="RTL">&bull; انخفاض مستويات الصفائح الدموية،</p><p dir="RTL">&bull; رد فعل تحسسي (مثل تورم في الفم واللسان والوجه والحلق، والحكة، والشري)،</p><p dir="RTL">&bull; بداية أو تفاقم مرض السكري، الحماض الكيتوني (الكيتونات في الدم والبول) أو الغيبوبة،</p><p dir="RTL">&bull; ارتفاع نسبة السكر في الدم،</p><p dir="RTL">&bull; كمية غير كافية من الصوديوم في الدم،</p><p dir="RTL">&bull; فقدان الشهية (ضعف الشهية)،</p><p dir="RTL">&bull; فقدان الوزن،</p><p dir="RTL">&bull; زيادة الوزن،</p><p dir="RTL">&bull; أفكار الانتحار، محاولة الانتحار والانتحار،</p><p dir="RTL">&bull; القمار المفرط،</p><p dir="RTL">&bull; الشعور بالعدوانية،</p><p dir="RTL">&bull; الإثارة،</p><p dir="RTL">&bull; العصبية،</p><p dir="RTL">&bull; مزيج من الحمى وتصلب العضلات وسرعة التنفس والتعرق وانخفاض الوعي والتغيرات المفاجئة في ضغط الدم ومعدل ضربات القلب، والإغماء (متلازمة الذهان الخبيثة)،</p><p dir="RTL">&bull; تشنج،</p><p dir="RTL">&bull; متلازمة السيروتونين (رد فعل قد يسبب الشعور بسعادة عظيمة، والتخبط، والأرق، والشعور وكأنك في حالة سكر، والحمى، والتعرق أو تصلب العضلات)،</p><p dir="RTL">&bull; اضطراب الكلام،</p><p dir="RTL">&bull; الموت المفاجئ غير المبرر،</p><p dir="RTL">&bull; ضربات القلب غير المنتظمة التي تهدد الحياة،</p><p dir="RTL">&bull; نوبة قلبية،</p><p dir="RTL">&bull; بطء ضربات القلب،</p><p dir="RTL">&bull; جلطات الدم في الأوردة وخاصة في الساقين (وتشمل الأعراض تورم وألم واحمرار في الساق)، والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين مما يسبب ألم في الصدر وصعوبة في التنفس (إذا لاحظت أي من هذه الأعراض، اطلب المشورة الطبية فورا)،</p><p dir="RTL">&bull; ارتفاع ضغط الدم،</p><p dir="RTL">&bull; الإغماء،</p><p dir="RTL">&bull; الاستنشاق العرضي للأغذية مع خطورة حدوث التهاب رئوي (عدوى الرئة)،</p><p dir="RTL">&bull; تشنج العضلات حول مربع الصوت،</p><p dir="RTL">&bull; التهاب البنكرياس،</p><p dir="RTL">&bull; صعوبة في البلع،</p><p dir="RTL">&bull; إسهال،</p><p dir="RTL">&bull; الشعور بعدم الارتياح في البطن،</p><p dir="RTL">&bull; الشعور بعدم الراحة في المعدة،</p><p dir="RTL">&bull; التليف الكبدى،</p><p dir="RTL">&bull; التهاب الكبد،</p><p dir="RTL">&bull; اصفرار الجلد والجزء الأبيض من العينين،</p><p dir="RTL">&bull; تقارير عن نتائج غير طبيعية لاختبارات الكبد،</p><p dir="RTL">&bull; الطفح الجلدي،</p><p dir="RTL">&bull; حساسية للضوء،</p><p dir="RTL">&bull; الصلع،</p><p dir="RTL">&bull; التعرق الزائد،</p><p dir="RTL">&bull; انهيار للعضلات غير طبيعي والذي يمكن أن يؤدي إلى مشاكل في الكلى،</p><p dir="RTL">&bull; ألم عضلي،</p><p dir="RTL">&bull; التصلب،</p><p dir="RTL">&bull; خروج البول بطريقة لاإرادية (سلس البول)،</p><p dir="RTL">&bull; صعوبة في تمرير البول،</p><p dir="RTL">&bull; أعراض الانسحاب لدى الأطفال حديثي الولادة في حالة التعرض أثناء الحمل،</p><p dir="RTL">&bull; الانتصاب المطول و / أو المؤلم،</p><p dir="RTL">&bull; صعوبة في التحكم في درجة حرارة الجسم الأساسية أو ارتفاع درجة الحرارة،</p><p dir="RTL">&bull; ألم في الصدر،</p><p dir="RTL">&bull; تورم اليدين والكاحلين أو القدمين،</p><p dir="RTL">&bull; في اختبارات الدم: تذبذب نسبة السكر في الدم، وزيادة الهيموجلوبين الجليكوزيلاتي.</p><p dir="RTL">في المرضى المسنين المصابين بالخرف، تم الإبلاغ عن حالات أكثر فتكا أثناء تناول أريبيبرازول. وبالإضافة إلى ذلك، تم الإبلاغ عن حالات السكتة الدماغية أو السكتة الدماغية &quot;البسيطة&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية إضافية في الأطفال والمراهقين</strong></p><p dir="RTL">المراهقين الذين تتراوح أعمارهم بين 13 سنة فيما أكثر يتعرضوا لأعراض جانبية مماثلة في معدل الحدوث والنوع لتلك الموجودة في البالغين إلا أن النعاس، الارتعاش الذي لا يمكن السيطرة عليه أو الحركات الارتجاجية، والأرق، والتعب كانت شائعة جدا (أكثر من 1 من كل 10 مرضى) وآلام في الجزء العلوي من البطن، جفاف الفم، وزيادة معدل ضربات القلب، وزيادة الوزن، وزيادة الشهية، وارتعاش العضلات، والحركات غير المنضبطة للأطراف، والشعور بالدوار، وخاصة عند الاستيقاظ من وضع الرقود أو الجلوس، كانت شائعة (أكثر من 1 من 100 مريض).</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ والسلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يحفظ بعيدا عن متناول ونظر الاطفال.</p><p dir="RTL">لا تستعمل <strong>أريبيكس</strong> بعد انتهاء تاريخ الصلاحية المدون على الشريط والعبوة.</p><p dir="RTL">يحفظ فى العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تحتاج إليها. فسوف تساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">المادة الفعالة هى أريبيبرازول</li></ul><p dir="RTL">أقراص أريبيكس 5 ملجم: يحتوي كل قرص على 5 ملجم أريبيبرازول.</p><p dir="RTL">أقراص أريبيكس 10 ملجم: يحتوي كل قرص على 10 ملجم أريبيبرازول.</p><p dir="RTL">أقراص أريبيكس 15 ملجم: يحتوي كل قرص على 15 ملجم أريبيبرازول.</p><ul><li dir="RTL">المواد الأخرى هى: ستيارات المغنسيوم، أفيسيل بى إتش 102، كروسكارميللوز صوديوم نوع A، أكسيد حديد أحمر، أكسيد حديد أصفر، لاكتوز سريع التدفق وسبيكتراكول بريليانت أزرق إل كي 815030.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أقراص أريبيكس 5 ملجم: أقراص غير مغلفة لونها أزرق فاتح، مستديرة، ثنائية التحدب محفورة ب &ldquo;T32&rdquo; على جانب واحد وخالية من العلامات على الجانب الأخر.</p><p dir="RTL" style="text-align:right">أقراص أريبيكس 10 ملجم: أقراص غير مغلفة لونها وردى فاتح، مستديرة، ثنائية التحدب محفورة ب &ldquo;T33&rdquo; على جانب واحد وخالية من العلامات على الجانب الأخر.</p><p dir="RTL" style="text-align:right">أقراص أريبيكس 15 ملجم: أقراص غير مغلفة لونها أصفر فاتح، مستديرة، ثنائية التحدب محفورة ب &ldquo;T34&rdquo; على جانب واحد وخالية من العلامات على الجانب الأخر.</p><p dir="RTL" style="text-align:right">تحتوي كل عبوة على 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صنع بواسطة</strong><strong>:</strong></p><p dir="RTL"><strong>الدمام فارما</strong></p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2017.                               
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ARIPEX 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Tablets
Each 5 mg tablet contains 5 mg of aripiprazole as an active ingredient and 55.86 mg of Lactose fast flow as excipient, For a full list of excipients see section 6.1
Each 10 mg tablet contains 10 mg of aripiprazole as an active ingredient and 51.03 mg of Lactose fast flow as excipient, For a full list of excipients see section 6.1
Each 15 mg tablet contains 15 mg of aripiprazole as an active ingredient and 45.85 mg of Lactose fast flow as excipient, For a full list of excipients see section 6.1
	

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Tablets
5 mg: A light blue, round, biconvex uncoated tablet, engraved with "T32"on one side and plain on the other side.
10 mg: A light pink, round, biconvex uncoated tablets engraved with "T33"on one side and plain on the other side.
15 mg: A light yellow, round, biconvex uncoated tablets engraved with "T34"on one side and plain on the other side.
	

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>ARIPEX is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.</p><p>ARIPEX is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</p><p>ARIPEX is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p><strong>Posology</strong></p><p><u>Adults:</u></p><p><em>Schizophrenia:</em>&nbsp;the recommended starting dose for ARIPEX is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ARIPEX is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p><em>Manic episodes:</em> The recommended starting dose for ARIPEX is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p><em>Recurrence prevention of manic episodes in Bipolar I Disorder</em>: For preventing recurrence of manic episodes in patients who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</p><p><u>Pediatric population:</u></p><p><em>Schizophrenia in adolescents 15 years and older:</em> the recommended dose for ARIPEX is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1).</p><p>ARIPEX is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated in adolescents although individual patients may benefit from a higher dose.</p><p>ARIPEX is not recommended for use in patients below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</p><p><em>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</em>: the recommended dose for ARIPEX is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg (using ARIPEX oral solution 1 mg/ml) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant undesirable effects including EPS related events, somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ARIPEX is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</p><p><em>Irritability associated with autistic disorder:</em> the safety and efficacy of ARIPEX in children and adolescents below 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>Tics associated with Tourette&#39;s disorder:&nbsp;the safety and efficacy of ARIPEX in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><u>Patients with hepatic impairment</u>: no dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</p><p><u>Patients with renal impairment</u>: no dosage adjustment is required in patients with renal impairment.</p><p><u>Elderly</u>: the effectiveness of ARIPEX in the treatment of schizophrenia and Bipolar I Disorder in patients 65 years of age or older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</p><p><u>Gender</u>: no dosage adjustment is required for female patients as compared to male patients (see section 5.2).</p><p><u>Smoking status</u>: according to the metabolic pathway of ARIPEX no dosage adjustment is required for smokers (see section 4.5).</p><p><u>Dose adjustments due to interactions</u>:</p><p>When concomitant administration of potent CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</p><p>When concomitant administration of potent CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</p><p><strong>Method of administration</strong></p><p>ARIPEX tablets for oral use.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 	
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</p><p>&nbsp;</p><p><u>Suicidality</u></p><p>The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic therapy.</p><p>&nbsp;</p><p>Results of an epidemiological study suggested that there was no increased risk of suicidality with aripiprazole compared to other antipsychotics among adult patients with schizophrenia or bipolar disorder. There are insufficient paediatric data to evaluate this risk in younger patients (below 18 years of age), but there is evidence that the risk of suicide persists beyond the first 4 weeks of treatment for atypical antipsychotics, including aripiprazole.</p><p><u>Cardiovascular disorders:</u></p><p>Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with ARIPEX and preventive measures undertaken.</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p>In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. As with other antipsychotics, aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</p><p><u>Tardive dyskinesia</u>:</p><p>In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on ARIPEX, dose reduction or discontinuation should be considered. These symptoms can temporarily deteriorate or can even arise after discontinuation of treatment.</p><p>&nbsp;</p><p><u>Other extrapyramidal symptoms</u></p><p>In paediatric clinical trials of aripiprazole akathisia and parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</p><p><u>Neuroleptic Malignant Syndrome (NMS)</u>:</p><p>NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicinal products, including ARIPEX, must be discontinued.</p><p><u>Seizure</u>:</p><p>In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</p><p><u>Elderly patients with dementia-related psychosis</u></p><p>&nbsp;</p><p><em>Increased mortality</em></p><p>&nbsp;</p><p>In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer&#39;s disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</p><p><em>Cerebrovascular adverse reactions</em>:</p><p>In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78-88 years). Overall, 1.3% of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6% of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</p><p>ARIPEX is not indicated for the treatment of dementia-related psychosis.</p><p><u>Hyperglycemia and diabetes mellitus</u>:</p><p>Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotic agents, including ARIPEX. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycemia-related adverse reactions (including diabetes) or in abnormal glycemia laboratory values compared to placebo. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with ARIPEX and with other atypical antipsychotic agents are not available to allow direct comparisons. Patients treated with any antipsychotic agents, including ARIPEX, should be observed for signs and symptoms of hyperglycemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</p><p><u>Hypersensitivity</u>:</p><p>As with other medicinal products, hypersensitivity reactions, characterized by allergic symptoms, may occur with aripiprazole (see section 4.8).</p><p><u>Weight gain</u>:</p><p>Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed ARIPEX. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</p><p><u>Dysphagia</u>:</p><p>Esophageal dysmotility and aspiration have been associated with antipsychotic treatment, including ARIPEX. Aripiprazole and other antipsychotic active substances should be used cautiously in patients at risk for aspiration pneumonia.</p><p>&nbsp;</p><p><u>Pathological gambling</u></p><p>Post-marketing reports of pathological gambling have been reported among patients prescribed aripiprazole, regardless of whether these patients had a prior history of gambling. Patients with a prior history of pathological gambling may be at increased risk and should be monitored carefully (see section 4.8).</p><p><u>Intolerance:</u></p><p><em>Tablets: </em>ARIPEX tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><u>Patients with ADHD comorbidity</u></p><p>Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its &alpha;<sub>1</sub>-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.</p><p>Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is taken in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</p><p>If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</p><p><u>Potential for other medicinal products to affect ARIPEX</u>:</p><p>A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant.</p><p>Aripiprazole is metabolized by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</p><p><em>Quinidine and other CYP2D6 inhibitors</em></p><p>In a clinical trial in healthy subjects, a potent inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107%, while C<sub>max</sub> was unchanged. The AUC and C<sub>max</sub> of dehydro-aripiprazole, the active metabolite, decreased by 32% and 47%. ARIPEX dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of ARIPEX with quinidine occurs. Other potent inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</p><p><em>Ketoconazole and other CYP3A4 inhibitors</em></p><p>In a clinical trial in healthy subjects, a potent inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max</sub> by 63% and 37%, respectively. The AUC and C<sub>max</sub> of dehydro-aripiprazole increased by 77% and 43%, respectively. In CYP2D6 poor metabolizes, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with ARIPEX, potential benefits should outweigh the potential risks to the patient. When concomitant administration of ketoconozole with ARIPEX occurs, ARIPEX dose should be reduced to approximately one-half of its prescribed dose. Other potent inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors, may be expected to have similar effects and similar dose reductions should therefore be applied.</p><p>Upon discontinuation of the CYP2D6 or 3A4 inhibitor, the dosage of ARIPEX should be increased to the level prior to the initiation of the concomitant therapy.</p><p>When weak inhibitors of CYP3A4 (e.g., diltiazem or escitalopram) or CYP2D6 are used concomitantly with ARIPEX, modest increases in aripiprazole concentrations might be expected.</p><p><em>Carbamazepine and other CYP3A4 inducers</em></p><p>Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the geometric means of C<sub>max</sub> and AUC for aripiprazole were 68% and 73% lower, respectively, compared to when aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of C<sub>max</sub> and AUC after carbamazepine co-administration were 69% and 71% lower, respectively, than those following treatment with aripiprazole alone.</p><p>ARIPEX dose should be doubled when concomitant administration of ARIPEX occurs with carbamazepine. Other potent inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John&#39;s Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of potent CYP3A4 inducers, the dosage of ARIPEX should be reduced to the recommended dose.</p><p>When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations.</p><p>&nbsp;</p><p><em>Serotonin syndrome</em></p><p>&nbsp;</p><p>Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</p><p><u>Potential for ARIPEX to affect other medicinal products:</u></p><p>In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), 2C9 (warfarin), 2C19 (omeprazole), and 3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <em>in vitro</em>. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</p><p>When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p><u>Pregnancy</u></p><p>Pregnancy category C</p><p>There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the fetus.</p><p>Neonates exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p><u>Breast-feeding</u></p><p>Aripiprazole was excreted in the milk of treated rats during lactation. It is not known whether aripiprazole is excreted in human milk. Patients should be advised not to breast feed if they are taking aripiprazole.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>As with other antipsychotics, patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that aripiprazole does not affect them adversely (see section 4.8).</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions in placebo-controlled trials are akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.</p><p><u>Tabulated list of adverse reactions</u></p><p>All ADRs are listed by system organ class and frequency; very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia</p><p>Neutropenia</p><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperprolactinaemia</p></td><td style="vertical-align:top"><p>Diabetic hyperosmolar coma</p><p>Diabetic ketoacidosis</p><p>Hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Diabetes mellitus</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Hyponatremia</p><p>Anorexia</p><p>Weight decreased</p><p>Weight gain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia</p><p>Anxiety</p><p>Restlessness</p></td><td style="vertical-align:top"><p>Depression,</p><p>Hypersexuality</p></td><td style="vertical-align:top"><p>Suicide attempt, suicidal ideation and completed suicide (see section 4.4)</p><p>Pathological gambling</p><p>Aggression</p><p>Agitation</p><p>Nervousness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Akathisia</p><p>Extrapyramidal disorder</p><p>Tremor</p><p>Headache</p><p>Sedation</p><p>Somnolence</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Tardive dyskinesia</p><p>Dystonia</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome (NMS)</p><p>Grand mal convulsion</p><p>Serotonin syndrome</p><p>Speech disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Sudden unexplained death</p><p>Torsades de pointes</p><p>QT prolongation</p><p>Ventricular arrhythmias</p><p>Cardiac arrest</p><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)</p><p>Hypertension</p><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hiccups</p></td><td style="vertical-align:top"><p>Aspiration pneumonia</p><p>Laryngospasm</p><p>Oropharyngeal spasm</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Constipation</p><p>Dyspepsia</p><p>Nausea</p><p>Salivary hypersecretion</p><p>Vomiting</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p><p>Dysphagia</p><p>Diarrhoea</p><p>Abdominal discomfort</p><p>Stomach discomfort</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic failure</p><p>Hepatitis</p><p>Jaundice</p><p>Increased Alanine Aminotransferase (ALT)</p><p>Increased Aspartate Aminotransferase (AST)</p><p>Increased Gamma Glutamyl Transferase (GGT)</p><p>Increased alkaline phosphatase</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p><p>Photosensitivity reaction</p><p>Alopecia</p><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Myalgia</p><p>Stiffness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Urinary incontinence</p><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Temperature regulation disorder (e.g. hypothermia, pyrexia)</p><p>Chest pain</p><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood glucose increased</p><p>Glycosylated haemoglobin increased</p><p>Blood glucose fluctuation</p><p>Increased creatine phosphokinase</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em>Extrapyramidal symptoms (EPS)</em></p><p><em>Schizophrenia:</em>&nbsp;in a long term 52-week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</p><p><em>Manic episodes in Bipolar I Disorder:&nbsp;</em>in a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</p><p><em>Akathisia</em></p><p>In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</p><p><em>Dystonia</em></p><p>Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p><em>Prolactin</em></p><p>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</p><p><em>Laboratory parameters</em></p><p>Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</p><p><u>Paediatric population</u></p><p><em>Schizophrenia in adolescents aged 15 years and older</em></p><p>In a short-term placebo-controlled clinical trial involving 302 adolescents (13-17 years) with schizophrenia, the frequency and type of undesirable effects were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</p><p>somnolence/sedation and extrapyramidal disorder were reported very commonly (&ge; 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (&ge; 1/100, &lt; 1/10). The safety profile in a 26-week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial.</p><p>The safety profile of a long-term, double-blind placebo controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (&ge; 1/100, &lt; 1/10).</p><p>In the pooled adolescent schizophrenia population (13-17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 29.5 % and 48.3 %, respectively. In the adolescent (13-17 years) schizophrenia population with aripiprazole exposure of 5 to 30 mg up to 72 months, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 25.6 % and 45.0 %, respectively.</p><p>In two long term trials with adolescent (13-17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt;2 ng/ml) was 37.0 % and 59.4 %, respectively.</p><p><em>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</em></p><p>The frequency and type of undesirable effects in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (&ge; 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (&ge; 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</p><p>The following undesirable effects had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %, 30 mg, 28.8 %, placebo, 1.7 %,); and akathisia (incidences were 10 mg, 12.1 %, 30 mg, 20.3 %, placebo, 1.7 %).</p><p>Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</p><p>In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</p><p>In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) was 28.0 % and 53.3 %, respectively.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions&nbsp;via:</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:49.45pt;margin-top:12.75pt;width:377.2pt;height:106.65pt;
 z-index:251657216;mso-width-relative:margin;mso-height-relative:margin'>
 <v:textbox style='mso-next-textbox:#_x0000_s1026'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s)</strong><strong>:</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p><u>Signs and symptoms</u></p><p>In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.</p><p><u>Management of overdose</u></p><p>Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</p><p>Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<sub>max</sub> by about 41% and AUC by about 51%, suggesting that charcoal may be effective in the treatment of overdose.</p><p><u>Haemodialysis</u></p><p>Although there is no information on the effect of hemodialysis in treating an overdose with aripiprazole, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Pharmacotherapeutic group: other antipsychotics, ATC code: N05AX12</p><p><u>Mechanism of action</u></p><p>It has been proposed that aripiprazole&#39;s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptors and antagonism of serotonin 5HT2a receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <em>in vitro</em> for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1 adrenergic and histamine H1 receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</p><p>Aripiprazole doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.</p><p><u>Clinical efficacy and safety</u></p><p>Schizophrenia in adults:</p><p>In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</p><p>ARIPEX is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77% and haloperidol 73%). The overall completion rate was significantly higher for patients on aripiprazole (43%) than for haloperidol (30%). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol.</p><p>In a 26-week, placebo-controlled trial in stabilized patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34% in aripiprazole group and 57% in placebo.</p><p>Weight gain:</p><p>In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 patients and where the primary end-point was weight gain, significantly less patients had at least 7% weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (N= 18, or 13% of evaluable patients), compared to olanzapine (N= 45, or 33% of evaluable patients).</p><p>Lipid parameters:</p><p>In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, HDL and LDL.</p><p>-Total cholesterol: incidence of changes in levels from normal (&lt;5.18 mmol/l) to high (<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_6" o:spid="_x0000_i1025" type="#_x0000_t75"
   alt="GREATER-THAN OR EQUAL TO (8805)" style='width:9pt;height:9pt;
   visibility:visible'>
   <v:imagedata src="file:///C:/Users/nooon/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="GREATER-THAN OR EQUAL TO (8805)"/>
  </v:shape><![endif]-->&ge; 6.22 mmol/l) was 2.5% for aripiprazole and 2.8% for placebo and mean change from baseline was -0.15 mmol/l (95% CI: -0.182, -0.115) for aripiprazole and -0.11 mmol/l (95% CI: -0.148, -0.066) for placebo.</p><p>-Fasting triglycerides: incidence of changes in levels from normal (&lt;1.69 mmol/l) to high (<!--[if gte vml 1]><v:shape id="Picture_x0020_7"
   o:spid="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
   style='width:9pt;height:9pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/nooon/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="GREATER-THAN OR EQUAL TO (8805)"/>
  </v:shape><![endif]-->&ge; 2.26 mmol/l) was 7.4% for aripiprazole and 7.0% for placebo and mean change from baseline was -0.11 mmol/l (95% CI: -0.182, -0.046) for aripiprazole and -0.07 mmol/l (95% CI: -0.148, 0.007) for placebo.</p><p>-HDL: incidence of changes in levels from normal (<!--[if gte vml 1]><v:shape
   id="Picture_x0020_8" o:spid="_x0000_i1027" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
   style='width:9pt;height:9pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/nooon/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="GREATER-THAN OR EQUAL TO (8805)"/>
  </v:shape><![endif]-->&ge; 1.04 mmol/l) to low (&lt;1.04 mmol/l) was 11.4% for aripiprazole and 12.5% for placebo and mean change from baseline was -0.03 mmol/l (95% CI: -0.046, -0.017) for aripiprazole and -0.04 mmol/l (95% CI: -0.056, -0.022) for placebo.</p><p>-Fasting LDL: incidence of changes in levels from normal (&lt;2.59 mmol/l) to high (<!--[if gte vml 1]><v:shape id="Picture_x0020_9" o:spid="_x0000_i1028"
   type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)" style='width:9pt;
   height:9pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/nooon/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="GREATER-THAN OR EQUAL TO (8805)"/>
  </v:shape><![endif]-->&ge; 4.14 mmol/l) was 0.6% for aripiprazole and 0.7% for placebo and mean change from baseline was -0.09 mmol/l (95% CI: -0.139, -0.047) for aripiprazole and -0.06 mmol/l (95% CI: -0.116, -0.012) for placebo.</p><p>&nbsp;</p><p><em>Prolactin</em></p><p>&nbsp;</p><p>Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</p><p>&nbsp;</p><p>The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</p><p>&nbsp;</p><p>Manic episodes in Bipolar I Disorder:</p><p>In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</p><p>In one 3-week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</p><p>In two 12-week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</p><p>In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</p><p>In a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomization, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</p><p>In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Y-MRS and MADRS total scores <!--[if gte vml 1]><v:shape id="Picture_x0020_10"
   o:spid="_x0000_i1029" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
   style='width:9pt;height:9pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/nooon/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif"
    o:title="LESS-THAN OR EQUAL TO (8804)"/>
  </v:shape><![endif]-->&le;12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46% decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65% decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score (mania).</p><p>In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilized for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer.</p><p>Stabilized patients were then randomized to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomized phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate.</p><p>The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16% in aripiprazole + lithium and 18% in aripiprazole + valproate compared to 45% in placebo + lithium and 19% in placebo + valproate.</p><p><u>Pediatric population: </u></p><p>Schizophrenia in adolescents:</p><p>In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13-17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</p><p>In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74% of the total enrolled population, maintenance of effect was observed over the 26-week open-label extension trial.</p><p>&nbsp;</p><p>In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13-17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39%) and placebo (37.50%) groups. The point estimate of the hazard ratio (HR) was 0.461 (95% confidence interval, 0.242-0.879) in the full population. In subgroup analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13-14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95% confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</p><p>&nbsp;</p><p><em>Manic episodes in Bipolar I Disorder in children and adolescents</em></p><p>&nbsp;</p><p>Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score &ge; 20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.</p><p>&nbsp;</p><p>Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</p><p>&nbsp;</p><p><strong>Table 1: Mean improvement from baseline YMRS score by psychiatric comorbidity</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Psychiatric comorbidities</strong></p></td><td><p>Week 4</p></td><td><p>Week 12</p></td><td style="vertical-align:top"><p><strong>ADHD</strong></p></td><td><p>Week 4</p></td><td><p>Week 12</p></td></tr><tr><td style="vertical-align:top"><p>ARIPEX 10 mg</p><p>(n = 48)</p></td><td><p>14.9</p></td><td><p>15.1</p></td><td style="vertical-align:top"><p>ARIPEX 10 mg</p><p>(n = 44)</p></td><td><p>15.2</p></td><td><p>15.6</p></td></tr><tr><td style="vertical-align:top"><p>ARIPEX 30 mg</p><p>(n = 51)</p></td><td><p>16.7</p></td><td><p>16.9</p></td><td style="vertical-align:top"><p>ARIPEX 30 mg</p><p>(n = 48)</p></td><td><p>15.9</p></td><td><p>16.7</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(n = 52)<sup>a</sup></p></td><td><p>7.0</p></td><td><p>8.2</p></td><td style="vertical-align:top"><p>Placebo</p><p>(n = 47)<sup>b</sup></p></td><td><p>6.3</p></td><td><p>7.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>No psychiatric comorbidities</strong></p></td><td><p>Week 4</p></td><td><p>Week 12</p></td><td style="vertical-align:top"><p><strong>No ADHD</strong></p></td><td><p>Week 4</p></td><td><p>Week 12</p></td></tr><tr><td style="vertical-align:top"><p>ARIPEX 10 mg</p><p>(n = 27)</p></td><td><p>12.8</p></td><td><p>15.9</p></td><td style="vertical-align:top"><p>ARIPEX 10 mg</p><p>(n = 37)</p></td><td><p>12.7</p></td><td><p>15.7</p></td></tr><tr><td style="vertical-align:top"><p>ARIPEX 30 mg</p><p>(n = 25)</p></td><td><p>15.3</p></td><td><p>14.7</p></td><td style="vertical-align:top"><p>ARIPEX 30 mg</p><p>(n = 30)</p></td><td><p>14.6</p></td><td><p>13.4</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(n = 18)</p></td><td><p>9.4</p></td><td><p>9.7</p></td><td style="vertical-align:top"><p>Placebo</p><p>(n = 25)</p></td><td><p>9.9</p></td><td><p>10.0</p></td></tr></tbody></table><p><sup>a&nbsp;</sup>n = 51 at Week 4</p><p><sup>b&nbsp;</sup>n = 46 at Week 4</p><p>&nbsp;</p><p>The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment-interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</p><p>&nbsp;</p><p><em>Irritability associated with autistic disorder in paediatric patients (see section 4.2)</em></p><p>&nbsp;</p><p>Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</p><p>&nbsp;</p><p>Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13-26 week stabilisation on aripiprazole (2-15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17 % of patients, with tremor accounting for 6.5 %.</p><p>&nbsp;</p><p><em>Tics associated with Tourette&#39;s disorder in paediatric patients (see section 4.2)</em></p><p>&nbsp;</p><p>The efficacy of aripiprazole was studied in paediatric subjects with Tourette&#39;s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 - 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35,for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</p><p>&nbsp;</p><p>The efficacy of aripiprazole in paediatric subjects with Tourette&#39;s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in South-Korea. Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</p><p>&nbsp;</p><p>In both of these short term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with ARIPEX in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p><u>Absorption:</u></p><p>Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87%. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</p><p><u>Distribution:</u></p><p>Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99% bound to serum proteins, binding primarily to albumin.</p><p><u>Biotransformation:</u></p><p>Aripiprazole is extensively metabolized by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <em>in vitro</em> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.</p><p><u>Elimination:</u></p><p>The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</p><p>The total body clearance of aripiprazole is 0.7 ml/min/kg, which is primarily hepatic.</p><p>Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27% of the administered radioactivity was recovered in the urine and approximately 60% in the feces. Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% was recovered unchanged in the feces.</p><p><em><u>Pharmacokinetics in special patient groups</u></em></p><p><u>Pediatric population:</u></p><p>The pharmacokinetics of aripiprazole and dehydro-aripiprazole in pediatric patients 13 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</p><p><u>Elderly:</u></p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</p><p><u>Gender:</u></p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</p><p><em><u>Smoking</u></em></p><p>Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.</p><p>&nbsp;</p><p><em><u>Race</u></em></p><p>Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.</p><p><u>Renal impairment:</u></p><p>The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</p><p><u>Hepatic impairment:</u></p><p>A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.</p><p>Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</p><p>An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<sup>2</sup>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6% of the bile concentrations found in the monkeys in the 39-week study and are well below (6%) their limits of <em>in vitro</em> solubility.</p><p>In repeat dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse effects on development.</p><p>Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets:</p><p>&nbsp;</p><p>Magnesium Stearate</p><p>Avicel PH 102</p><p>Croscarmellose Sodium Type A</p><p>Red Iron Oxide</p><p>Yellow Iron Oxide</p><p>Spectracol Brilliant Blue LK815030</p><p>Lactose Fast Flow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Not Applicable</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets: 2  years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablets</u></p><p>Reel AL/OPA/PVC Blister and Aluminum Foil</p><p>Each pack contains 30 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
DAMMAM Pharma 
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>